Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis
S Singh, YK Loke, JG Spangler, CD Furberg - Cmaj, 2011 - Can Med Assoc
Background: There have been postmarketing reports of adverse cardiovascular events
associated with the use of varenicline, a widely used smoking cessation drug. We conducted …
associated with the use of varenicline, a widely used smoking cessation drug. We conducted …
Varenicline and adverse cardiovascular events: a systematic review and meta‐analysis of randomized controlled trials
LH Sterling, SB Windle, KB Filion, L Touma… - Journal of the …, 2016 - Am Heart Assoc
Background Varenicline is an efficacious smoking‐cessation drug. However, previous meta‐
analyses provide conflicting results regarding its cardiovascular safety. The publication of …
analyses provide conflicting results regarding its cardiovascular safety. The publication of …
Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis
JJ Prochaska, JF Hilton - Bmj, 2012 - bmj.com
Objective To examine the risk of treatment emergent, cardiovascular serious adverse events
associated with varenicline use for tobacco cessation. Design Meta-analysis comparing …
associated with varenicline use for tobacco cessation. Design Meta-analysis comparing …
Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial
NA Rigotti, AL Pipe, NL Benowitz, C Arteaga, D Garza… - Circulation, 2010 - Am Heart Assoc
Background—Smoking cessation is a key component of secondary cardiovascular disease
prevention. Varenicline, a partial α4β2 nicotinic acetylcholine receptor agonist, is effective …
prevention. Varenicline, a partial α4β2 nicotinic acetylcholine receptor agonist, is effective …
Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis
S Tonstad, S Davies, M Flammer, C Russ, J Hughes - Drug safety, 2010 - Springer
Abstract Background: Varenicline (Chantix®, Champix®) has shown efficacy and tolerability
as an aid to smoking cessation. In postmarketing surveillance, neuropsychiatric symptoms …
as an aid to smoking cessation. In postmarketing surveillance, neuropsychiatric symptoms …
[HTML][HTML] Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study
Background Varenicline is an effective pharmacotherapy to aid smoking cessation.
However, its use is limited by continuing concerns about possible associated risks of serious …
However, its use is limited by continuing concerns about possible associated risks of serious …
A preliminary benefit-risk assessment of varenicline in smoking cessation
K Cahill, L Stead, T Lancaster - Drug Safety, 2009 - Springer
Varenicline is a recently developed medication for smoking cessation, which has been
available on prescription since 2006. It is a selective nicotinic acetylcholine receptor partial …
available on prescription since 2006. It is a selective nicotinic acetylcholine receptor partial …
A double-blind study evaluating the long-term safety of varenicline for smoking cessation
KE Williams, KR Reeves, CB Billing Jr… - … medical research and …, 2007 - Taylor & Francis
Objective: We assessed the safety of long-term varenicline administration for smoking
cessation. Methods: In this randomized, double-blind, multicenter trial, eligible adult smokers …
cessation. Methods: In this randomized, double-blind, multicenter trial, eligible adult smokers …
Varenicline: a novel pharmacotherapy for smoking cessation
Varenicline is an orally administered small molecule with partial agonist activity at the α4β2
nicotinic acetylcholine receptor. Varenicline was approved by both the US FDA and the …
nicotinic acetylcholine receptor. Varenicline was approved by both the US FDA and the …
Varenicline: a first-line treatment option for smoking cessation
GD Garrison, SE Dugan - Clinical therapeutics, 2009 - Elsevier
Background: Varenicline acts as a partial agonist/antagonist with affinity and selectivity for
α4 β2 nicotinic acetylcholine receptors. This activity at the nicotine-receptor level may help …
α4 β2 nicotinic acetylcholine receptors. This activity at the nicotine-receptor level may help …
Related searches
- varenicline use meta analysis
- tobacco cessation meta analysis
- smoking cessation safety of varenicline
- smoking cessation benefit risk
- smoking cessation cardiovascular disease
- smoking cessation dosing strategy
- smoking cessation treatment option
- cardiovascular disease safety of varenicline
- smoking cessation efficacy and safety